Cefuroxime shortage — US supply status & alternatives

Cefuroxime

ATC J01DC02

🇦🇺 AUST R 388237 · Aspen Pharmacare Australia Pty Ltd

In supply · Australia

Ceftin Aprokam

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇺🇸 US🇧🇪 BE🇮🇳 IN

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$5.27DPMQ A$22.21details →

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

Expected back

Product attributes reference data we hold

Active ingredient (INN)	Cefuroxime
Brand names	Ceftin, Aprokam
ATC level 5	J01DC02
ATC level 4	J01DC
Therapeutic category	Auto-created by Health Canada — Drug Shortages Database scraper
Controlled substance	No
Marketing-authorisation holders	Aspen Pharmacare Australia Pty Ltd, HAMELN PHARMA LTD, SANDOZ LIMITED, Generics (UK) Limited +8 more
Registrations on file	25
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$5.27

AEMP

Dispensed (DPMQ)

A$22.21

incl. fees

Pack

cefuroxime 250 mg tablet, 20

Source: PBSEffective July 2026 · AUD

Other markets

🇺🇸 US

US$0.37

Acquisition

🇫🇷 FR

€4.69

Retail price

🇪🇸 ES

€4.84

Retail price

🇮🇹 IT

€5.60

Retail price

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

15 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Farmabios SPACovalent Laboratories Private LTDGlaxosmithkline LLCAcs Dobfar SPALupin LTDWockhardt LTD+9 more

Manufacturing countries: Italy, India, United States, China · Source: FDA List of Drug Master Files

Recalls official enforcement reports

🇺🇸

Cefuroxime

Pine Pharmaceuticals, LLC · Oct 2023

Class IIdetails ↗

🇺🇸

Cefuroxime

Edge Pharma, LLC · Dec 2021

Class IIdetails ↗

🇺🇸

Cefuroxime

Leiter's Enterprises, Inc. · Feb 2019

Class IIdetails ↗

🇺🇸

Cefuroxime

Pacific Compounding Pharmacy & Consultations Inc · Aug 2018

Class IIdetails ↗

🇺🇸

Cefuroxime

JCB Laboratories LLC · Jan 2018

Class IIIdetails ↗

🇺🇸

Cefuroxime Sodium

Leiter's Compounding · Sept 2016

Class IIdetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders25 registrations · 12 MA holders

Product	Strength	Form	Market	MA holder	Status
CEFINTRA cefuroxime	50 mg	—	🇦🇺 AU	Aspen Pharmacare Australia Pty Ltd	Active
CEFUROXIME 1.5 G POWDER FOR SOLUTION FOR INJECTION/INFUSION	1.5 G	injection	🇬🇧 GB	HAMELN PHARMA LTD	Active
CEFUROXIME 750 MG POWDER FOR SOLUTION/SUSPENSION FOR INJECTION	750 MG	injection	🇬🇧 GB	SANDOZ LIMITED	Active
CEFUROXIME 1500MG POWDER FOR SOLUTION FOR INJECTION/INFUSION	1500MG	injection	🇬🇧 GB	SANDOZ LIMITED	Active
CEFUROXIME 250MG TABLETS	250MG	tablet	🇬🇧 GB	SANDOZ LIMITED	Active
CEFUROXIME INJECTION 250MG	250MG	injection	🇬🇧 GB	Generics (UK) Limited	Active
CEFUROXIME INJECTION 750MG	750MG	injection	🇬🇧 GB	Generics (UK) Limited	Active
CEFUROXIME INJECTION 1.5G	1.5G	injection	🇬🇧 GB	Generics (UK) Limited	Active
CEFUROXIME 250MG POWDER FOR INJECTION	250MG	injection	🇬🇧 GB	ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI SPA	Active
CEFUROXIME 750 MG, POWDER FOR SOLUTION FOR INJECTION/INFUSION	750 MG	injection	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
CEFUROXIME 750MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION	750MG	injection	🇬🇧 GB	FLYNN PHARMA LIMITED	Active
CEFUROXIME 1.5G POWDER FOR SOLUTION FOR INJECTION OR INFUSION	1.5G	injection	🇬🇧 GB	FLYNN PHARMA LIMITED	Active
CEFUROXIME 50 MG POWDER FOR SOLUTION FOR INJECTION	50 MG	injection	🇬🇧 GB	CONSILIENT HEALTH LIMITED	Active
CEFUROXIME 250MG FILM-COATED TABLETS	250MG	tablet	🇬🇧 GB	ASCEND LABORATORIES (UK) LIMITED	Active
CEFUROXIME 500MG FILM-COATED TABLETS	500MG	tablet	🇬🇧 GB	ASCEND LABORATORIES (UK) LIMITED	Active

+10 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.